Skip to main content

Table 1 Characteristics of the included studies

From: Does potential antibody-dependent enhancement occur during SARS-CoV-2 infection after natural infection or vaccination? A meta-analysis

Study author, year

Country

Study type

Median age

Age range

Male(%,case/control)

Severe/immune

Severe/naive

Mild/immune

Mild/naive

NOS/Jadad

Adrielle Dos Santos Letícia et al. (2021)[23]

Brazil

Observational study

39.2

18–58

21.2/37.1

12

35

21

27

5

Hall et al. (2021)[12]

England

Observational study

45.7

18–85

17.2/14.9

50

1126

105

578

6

Murillo-Zamora et al. (2021)[13]

Mexico

Observational study

NA

 ≥ 20

NA

38

48,057

220

84,131

5

Bailly et al. (2021)[14]

France

Observational study

87.0

 ≥ 77

NA

2

4

11

1

5

Singh et al. (2021)[15]

India

Observational study

55.0

50–63

35.6/64.4

89

211

98

179

8

Slezak et al. (2021)[16]

America

Observational study

NA

 ≥ 15

NA

29

4094

286

71,055

6

Baden et al. (2020)[17]

America

RCT

51.4

 ≥ 18

52.2/53.1

4

43

7

142

6

Logunov et al. (2021)[18]

Russia

RCT

NA

 ≥ 18

61.1/61.5

0

20

16

42

8

Polack et al. (2020)[19]

Multinational

RCT

52

16–91

51.1/50.1

1

9

7

153

7

Sadoff et al. (2021)[20]

Multinational

RCT

52

 ≥ 18

55.1/54.7

14

60

103

291

7

Madhi et al. (2021)[21]

South Africa

RCT

NA

18–65

NA

4

6

15

17

6

  1. NA Not available, NOS Newcastle–Ottawa scale, Jadad Modified Jadad scale
  2. Severe/immune: Cases diagnosed as severe after natural infection/vaccination
  3. Severe/naive: Cases diagnosed as severe in the initial infection
  4. Mild/immune: Cases diagnosed as mild after natural infection/vaccination
  5. Mild/naive: Cases diagnosed as mild in the initial infection